Adcetris 50 mg Injection
PDF Leaflet Revision Date: 04 August 2020
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of CD30 positive cancers including Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Dosage (summary)
1.2 mg/kg IV infusion every 2 weeks for frontline HL; 1.8 mg/kg every 3 weeks for relapsed HL and sALCL.
Onset of Action / Duration
Onset: 30 mins, Duration: up to 16 cycles.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; men advised not to father a child during treatment and for 6 months after.
Key Drug Interactions
- CYP3A4 inhibitors/inducers
- Doxorubicin
- Vinblastine
- Dacarbazine
Contraindications
- Hypersensitivity
- Pregnancy
- Breastfeeding
- Combined use with bleomycin
Common side effects
- Neutropenia
- Peripheral neuropathy
- Nausea
- Fatigue
- Diarrhoea
Counselling Points
- Monitor for signs of infection
- Report any neurological symptoms
- Avoid pregnancy during treatment
Serious warnings
- Progressive multifocal leukoencephalopathy
- Acute pancreatitis
- Pulmonary toxicity
- Serious infections
Important Disclaimer
The Adcetris 50 mg Injection professional information leaflet below is the property of Takeda and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
